接受重症监护儿童的呼吸道合胞病毒相关疾病
该回顾性多中心队列研究纳入2017年1月1日至2023年6月1日期间2–17岁儿童RSV相关ICU入住共6430例次,占该年龄段全部ICU入住的8.3%。主要终点为住院死亡率,结果为7.5%(484例),且93.8%的死亡患儿至少存在1类CCC,68.6%存在≥3类CCC。≥3类CCC与死亡强烈相关(MOR 22.56,95%CI 15.44–32.97),恶性肿瘤、神经/神经肌肉、呼吸、移植等CCC类别在调整后仍与死亡相关。提示较大儿童和青少年RSV重症负担可观,死亡集中于CCC患儿,高危亚组可能从RSV预防中获益。
要点
- 住院死亡484例(7.5%),占全年龄段RSV相关死亡735例的65.9%,死亡高度集中于该年龄段ICU人群。
- 57.2%的入住至少合并1类CCC,但死亡病例中93.8%有≥1类CCC、68.6%有≥3类CCC,CCC负荷是死亡的核心风险分层因素。
- ≥3类CCC与死亡的MOR为22.56(95%CI 15.44–32.97);调整后恶性肿瘤aMOR 4.27(95%CI 3.16–5.77)、神经/神经肌肉aMOR 2.66(95%CI 2.08–3.39)仍与死亡相关。
- 32.0%使用正压通气、27.8%使用血管活性药物、14.0%两者均用,提示该人群ICU资源消耗高。
适用人群与场景
- 2–17岁儿童,因RSV相关疾病入住ICU者;RSV通过实验室检测或诊断编码识别。
- 研究场景为多中心ICU,时间范围2017年1月1日至2023年6月1日;原文未提及具体排除标准。
诊断标准与关键阈值
- RSV相关ICU入住定义为实验室检测或诊断编码识别RSV,并结合ICU入住;原文未提及具体实验室方法或编码界值。
- CCC负荷按类别数分层:至少1类、3类及以上;原文未给出各类CCC的具体诊断条目清单。
处置流程与药物剂量
- 原文未提及具体处置流程或药物剂量方案;仅报告支持治疗使用情况:正压通气2061例次(32.0%)、血管活性药物1788例次(27.8%)、两者均用903例次(14.0%)。
红旗征与不能漏的情况
- 存在3类及以上CCC的RSV患儿死亡风险显著升高(MOR 22.56,95%CI 15.44–32.97),属需重点监护和积极处理的高危情况。
- 合并恶性肿瘤(aMOR 4.27,95%CI 3.16–5.77)、神经或神经肌肉疾病(aMOR 2.66,95%CI 2.08–3.39)、呼吸系统疾病(aMOR 2.36,95%CI 1.83–3.03)、移植(aMOR 2.18,95%CI 1.47–3.23)者死亡风险升高。
- 先天或遗传性疾病、代谢性疾病、心血管疾病及技术依赖在调整后仍与死亡相关(原文未给出对应aMOR数值)。
研究设计与关键结果
- 中位ICU住院时长2.9天(IQR 1.5–6.8),中位住院时长5.9天(IQR 3.0–14.3)。
- 主要终点住院死亡484例(7.5%),占全年龄段RSV相关死亡735例的65.9%。
- ≥3类CCC与死亡的MOR 22.56(95%CI 15.44–32.97);CCC负荷随年龄增长而增加,但在各年龄层均与死亡相关。
- 调整后与死亡相关的CCC类别:恶性肿瘤aMOR 4.27(95%CI 3.16–5.77)、神经或神经肌肉aMOR 2.66(95%CI 2.08–3.39)、呼吸aMOR 2.36(95%CI 1.83–3.03)、移植aMOR 2.18(95%CI 1.47–3.23);先天或遗传、代谢、心血管疾病及技术依赖亦相关(未给数值)。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:回顾性设计、依赖实验室检测或诊断编码识别RSV、CCC分类依赖既有编码;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 对2–17岁RSV相关ICU患儿,应常规评估CCC类别与数量,≥3类CCC者视为死亡高危并加强监护。
- 合并恶性肿瘤、神经/神经肌肉疾病、呼吸系统疾病、移植或技术依赖的RSV患儿,ICU期间需警惕死亡风险升高。
- 较大儿童和青少年RSV重症可占ICU RSV负担的8.3%,不应仅将RSV重症视为婴儿疾病;高危CCC患儿可能从RSV预防中获益。
- 原文未提供具体治疗干预措施,不能据此改变抗病毒、呼吸支持或循环支持的用药方案。
指南或共识出处
- JAMA Network Open(原文未提及具体指南或共识名称)
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Data defining respiratory syncytial virus (RSV)-associated critical illness, risk factors, and outcomes among older children and adolescents are limited. As RSV prevention options expand, improved characterization of RSV-associated disease burden across childhood is needed.
OBJECTIVES: To quantify RSV-associated intensive care unit (ICU) admissions and mortality among children aged 2 to 17 years and evaluate associations between pediatric complex chronic conditions (CCCs) and mortality.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort study was performed from January 1, 2017, to June 1, 2023, among children aged 2 to 17 years admitted to ICUs. Data were analyzed from January to March 2026.
EXPOSURE: RSV identified by laboratory testing or diagnosis codes.
MAIN OUTCOMES AND MEASURES: Primary outcome was hospital mortality. Bivariate associations between mortality and covariates were calculated, and multivariable logistic regression was used to identify variables associated with mortality.
RESULTS: This study included 6430 RSV-associated ICU admissions for children aged 2 to 17 years (8.3% of 77 395 ICU admissions; median [IQR] age, 6.6 [3.4-12.6] years; 3457 [53.8%] male). The median (IQR) ICU length of stay was 2.9 (1.5-6.8) days, and the median (IQR) hospital LOS was 5.9 (3.0-14.3) days. Positive pressure ventilation was used in 2061 admissions (32.0%), vasoactive agents in 1788 (27.8%), and both in 903 (14.0%). Hospital mortality occurred in 484 admissions (7.5%) and accounted for 484 of 735 RSV-associated deaths (65.9%) across all ages. At least 1 CCC category was present in 3680 admissions (57.2%) and 454 of 484 deaths (93.8%); 3 or more CCC categories were present in 1666 admissions (25.9%) and 332 of 484 deaths (68.6%). Higher CCC burden was associated with mortality, particularly with 3 or more CCCs (mortality odds ratio [MOR 22.56; 95% CI, 15.44-32.97). CCC burden was associated with older age but remained associated with mortality across age strata. In adjusted analyses, malignant neoplasm (adjusted MOR ([aAMOR), 4.27 [95% CI, 3.16-5.77]), neurologic or neuromuscular (aAMOR, 2.66 [95% CI, 2.08-3.39]), respiratory (aAMOR, 2.36 [95% CI, 1.83-3.03]), transplant (aAMOR, 2.18 [95% CI, 1.47-3.23]), congenital or genetic, metabolic, and cardiovascular disease as well as technology dependence remained associated with mortality.
CONCLUSIONS AND RELEVANCE: In this cohort study of 6430 RSV-associated ICU admissions among children aged 2 to 17 years, older children and adolescents represented a substantial proportion of severe RSV-associated disease and mortality; deaths were concentrated among children with CCCs. These results suggest that high-risk pediatric subpopulations may benefit from RSV prevention.
参考来源
- Olson TL, Trujillo Rivera EA, Patel AK, et al. Respiratory Syncytial Virus-Associated Disease in Children Receiving Intensive Care. JAMA Netw Open. 2026. PMID: 42747852. doi:10.1001/jamanetworkopen.2026.34138
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。